As part of a private placement of Micromedic’s shares the general meeting of Micromedic shareholders approved BioLight investment conditions and upon completion of the assignment BioLight will hold approximately 46% of the issued and paid equity and about 46.17% in fully diluted basis.
Link to Newsroom